BioNeutra Global Corporation
BGACF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $11 | $13 | $15 | $24 |
| % Growth | -15% | -13.1% | -36.1% | – |
| Cost of Goods Sold | $7 | $11 | $13 | $20 |
| Gross Profit | $4 | $2 | $3 | $4 |
| % Margin | 36.4% | 17.5% | 18.8% | 16.4% |
| R&D Expenses | $0 | -$0 | $0 | $0 |
| G&A Expenses | $4 | $4 | $4 | $4 |
| SG&A Expenses | $4 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $1 | $1 | $2 |
| Operating Expenses | $6 | $5 | $5 | $7 |
| Operating Income | -$1 | -$2 | -$2 | -$3 |
| % Margin | -12.6% | -18.1% | -15.3% | -12.5% |
| Other Income/Exp. Net | -$1 | -$0 | -$0 | -$1 |
| Pre-Tax Income | -$2 | -$3 | -$3 | -$4 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$2 | -$3 | -$3 | -$4 |
| % Margin | -18.5% | -21.8% | -18.4% | -15.4% |
| EPS | -0.05 | -0.063 | -0.061 | -0.08 |
| % Growth | 20.5% | -3.3% | 23.9% | – |
| EPS Diluted | -0.045 | -0.063 | -0.061 | -0.08 |
| Weighted Avg Shares Out | 46 | 46 | 46 | 46 |
| Weighted Avg Shares Out Dil | 46 | 46 | 46 | 46 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $2 |
| EBITDA | -$0 | -$1 | -$1 | -$1 |
| % Margin | -3.1% | -10.2% | -7.2% | -6.2% |